Pediatric Psychopharmcology

Member Research Program


Pediatric Psychopharmcology

My primary interest involves the implications for learning, development, and behavior of the growth of psychotropic drug use for school-age youth. More specifically I am concerned about the potential deleterious impact on children and adolescents of (a) the serious adverse events that have been the subject of more than 30 U.S. Food and Drug Administration Drug Safety Communications since 1997, and (b) the less serious but far more common side effects that accompany psychotropic drug use in the pediatric population. I also have interest in the policies and processes (e.g., risk-benefit analyses) that encourage the prescription of psychotropic drugs as first-line treatments in the pediatric population, even when psychosocial interventions have demonstrated and comparable efficacy and superior safety.
Bronfenbrenner's bioecological model (1994, 2005).
Bronfenbrenner, U. & Ceci, S., J. (1994). Nature-nurture reconceptualized in developmental perspective: A bioecological model. Psychological Review, 104, 568-586. Bronfenbrenner, U. (2005). Making Human Beings Human: Biological Perspectives on Human Development.
FDA adverse event and side effect data are published on the FDA website but the site can be challenging to navigate to find relevant data. We have located all data for clinical trials that include or are exclusive to the pediatric population and identified side effects that are most common to drug categories (i.e., ADHD drugs, antidepressants, antipsychotics). These data were analyzed and have revealed both substantial differences in side effects for drugs within each class and discrepancies with side effects reported in clinical practice and published textbooks.
Because raw clinical trial data is proprietary to pharmaceutical manufacturers we have not been able to analyze those data. Instead we have employed methods used in epidemiology research (e.g., odds and risk ratios, Cochran Mantel-Haenszel techniques) to analyze for statistical significance of the differences we observed in the FDA data sets.
Adverse event and side effect data: www.fda.gov/Drugs/default.htm Statistical analysis: Borenstein, Hedges, Higgins, & Rothstein, 2009; Higgins & Green, 2009 Holcomb, Chaiworapongsa, Luke & Burgdorf, 2001 Knoll, Duijnhoven, Grobbee, Moons, & Groenwold, 2011 Woodward, 2004
Mire, S.S., Gealy, W., Kubiszyn, T., Burridge, A.B. & Goin-Kochel, R.P. (2015). Parent perceptions about autism spectrum disorder influence treatment choices. Focus on Autism and Other Developmental Disabilities. DOI:10.1177/1088357615610547 Mire, S.S., Nowell, K.P., Kubiszyn, T., & Goin-Kochel, R.P. (2014). Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related? Autism: The International Journal of Research and Practice, 18(8), 933-942. Kubiszyn, T. & Mire, S. S. (2014). Recent FDA Drug Safety Communications for Pediatric Psychotropics. Journal of Child and Family Studies. 23, 4, 716-727. Kubiszyn, T., Mire, S., Dutt, S. Papathopoulos, K. & Burridge, A. (2012). Significant differences in pediatric psychotropic sides effects: Implications for school behavior and performance. School Psychology Quarterly, 27, 4-28. Kubiszyn, T. (2011). Pediatric Psychopharmacology. In Bray, M. & Kehle, T. (Eds.). Oxford Handbook of School Psychology (pp. 696-727). Oxford University Press: New York. Kubiszyn, T. (2005). The Division 16 Task Force on Psychopharmacology, Learning and Behavior: An overview. School Psychology Quarterly, 20, 115-117. Kubiszyn, T., Carlson, J. C., & DeHay, T. (2005). Pediatric psychopharmacology for prepubertal internalizing disorders. School Psychology Quarterly, 20, 135-154. McClure, E. B., Kubiszyn, T., & Kaslow, N. J. (2002). Advances in the diagnosis and treatment of childhood mood disorders. Professional Psychology: Research and Practice, 33, 125-134. Kubiszyn, T., & Carlson, C. I. (1995). School psychologists' attitudes toward an expanded health care role: Psychopharmacology and prescription privileges. School Psychology Quarterly, 10, 247 270. Kubiszyn, T. (1994). Pediatric psychopharmacology and prescription privileges: Implications and opportunities for school psychology. School Psychology Quarterly, 9, 26 40. Carlson, C. I., & Kubiszyn, T. (1994). Prescription privileges, psychopharmacology and school psychology: An overview. School Psychology Quarterly, 9, 1 3.
Assessment
Professional Issues
Social-emotional interventions
Psychopharmacology
Professional Issues in School Psychology
Intervention, Social-emotional
Health Promotion


Announcements

  • The SSSP Board Meeting during the NASP Convention will be held Thursday, February 15, 2018 from 12 to 4 at Swissotel (connected to the Hyatt) MT069.
  • The SSSP Member’s Meeting and Reception will be held Thursday, February 15, 2018 from 5 to 7 at Maggiano’s Downtown Chicago, 516 North Clark Street, Chicago, IL 60654.